<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157987</url>
  </required_header>
  <id_info>
    <org_study_id>2013-004390-27</org_study_id>
    <nct_id>NCT02157987</nct_id>
  </id_info>
  <brief_title>Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose</brief_title>
  <acronym>EROSB</acronym>
  <official_title>Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epistaxis are present in over 90 % of patients with Rendu - Osler . They involve no&#xD;
      significant difference 2 sexes. They often appear in childhood and adolescence and are&#xD;
      present in three-quarters of patients at the age of 20 years. These epistaxis increasing in&#xD;
      frequency and volume to the age of 60 in 2/3 of patients. Epistaxis are spontaneous ,&#xD;
      repetitive and recurring . They are highly variable in duration, intensity and frequency of&#xD;
      occurrence . Some patients may have more than 40 monthly episodes with mean duration of 5&#xD;
      minutes of bleeding and chronic anemia and can sometimes acute anemia with transfusions need&#xD;
      to be source. These epistaxis stigmatize patients and inevitably affect their quality of life&#xD;
      and social skills . The various proposed ( cauterization , intra- mucosal injections, laser&#xD;
      selective hémostatses , embolization or surgical dermoplasties ) allow for some short-term&#xD;
      remissions . Bevacizumab is an antiangiogenic use in the treatment of colorectal cancers . It&#xD;
      is also used in ophthalmology intravitreal to reduce vascular proliferation in glaucoma&#xD;
      retinopathy and certain corneal neovascularization. In 2009, Prithviraj reported the use of&#xD;
      bevacizumab injection to treat pulmonary arteriovenous malformations in a patient with Rendu&#xD;
      - Osler . The result is doubly interesting including a saving action on epistaxis which&#xD;
      decrease in frequency and duration. This communication prompted the authors to focus more on&#xD;
      this medication. The product has been used in local submucosal injection intranasal laser was&#xD;
      coupled with satisfactory results objectified by a decrease in the number of epistaxis ,&#xD;
      reducing blood transfusions and improved social lives. The use of local instillation&#xD;
      bevacuzimab represents a way forward for the treatment of these epistaxis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease of at least 50% of number of epistaxis in a month compared to the month before inclusion.</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Telangiectasia, Hereditary Hemorrhagic</condition>
  <arm_group>
    <arm_group_label>bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bevacizumab spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacuzimab spray</intervention_name>
    <arm_group_label>bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with Rendu-Osler-Weber disease&#xD;
&#xD;
          -  patients with iterative epistaxis (at least 10 per month)&#xD;
&#xD;
          -  patients without treatment for 3 months with usual techniques (for the epistaxis)&#xD;
&#xD;
          -  patients speaking french fluently&#xD;
&#xD;
          -  patients with written consents&#xD;
&#xD;
          -  affiliation to social security&#xD;
&#xD;
          -  women with effective contraception during the treatment and for 6 months after&#xD;
             stopping&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General criteria:&#xD;
&#xD;
          -  Pregnant women, breastfeeding&#xD;
&#xD;
          -  Hypersensitivity to the active substance or any of its excipients&#xD;
&#xD;
          -  Hypersensitivity to the products of Chinese hamster ovary cells or other human or&#xD;
             humanized recombinant antibodies&#xD;
&#xD;
          -  Inability to undergo medical monitoring due to reasons geographical, social or&#xD;
             psychological&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Patient included in another biomedical research protocol&#xD;
&#xD;
        Related to medical history criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension ( systolic BP &gt; or = 150 mmHg and / or Diastolic BP &gt; or =&#xD;
             100 mmHg)&#xD;
&#xD;
          -  Thrombocytopenia &lt;100 G / L&#xD;
&#xD;
          -  Taking NSAIDs within ten days prior to inclusion&#xD;
&#xD;
          -  Anticoagulant therapy or thrombolytic within 28 days before inclusion&#xD;
&#xD;
          -  Tumor, genetic predisposition to bleeding, coagulopathy , patient receiving treatment&#xD;
             full anticoagulant dose for an event thromboembolism prior to inclusion&#xD;
&#xD;
          -  Major surgery within 28 days prior to inclusion&#xD;
&#xD;
          -  History of thromboembolic disease within 6 months prior to enrollment&#xD;
&#xD;
          -  Arteriovenous malformation localized to the brain, liver or lung on scanner older than&#xD;
             5 years&#xD;
&#xD;
          -  History of heart failure&#xD;
&#xD;
          -  Patients with proteinuria / creatinine greater than 2g / g&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laetitia ROBARD, MD</last_name>
    <phone>33231064388</phone>
    <email>robard-l@chu-caen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanuel BABIN, MD-PHD</last_name>
    <phone>33231064388</phone>
    <email>babin-e@chu-caen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Babin Emmanuel, MD PhD</last_name>
      <phone>33231064388</phone>
      <email>babin-e@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Robard Laetitia, MD</last_name>
      <phone>33231064388</phone>
      <email>robard-l@chu-caen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Robard Laetitia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Babin Emmanuel, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zalcman Gérard, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>telangietasia hereditary hemorragic</keyword>
  <keyword>epistaxis</keyword>
  <keyword>safety</keyword>
  <keyword>quality of life</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>spray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

